Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid, presented at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL.

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in Bullous Pemphigoid were presented last Saturday at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL.

Pr. Neil Korman, MD, PhD, FAAD spoke on March, 4th 2017 at the F076 – AUTOIMMUNE BLISTERING DISEASES: WHAT’S NEW scientific session, directed by Pr. Dedee F. Murrell, MD, FAAD.

Click the following link to access Pr. Neil Korman’s presentation.

 This was an advanced session for dermatologists already knowledgeable about the basics of blistering diseases. It focused on what is new in the field, including some new diagnostic tests which have become available to more rapidly distinguish one form of blistering disease from another. It also informed attendees about the evidence regarding the use of certain biologics in use or in development and clinical trials, for pemphigus and pemphigoid. Lastly, it explored the evidence that is known about environmental triggers in susceptible populations which leads to the development of pemphigus, using fogo selvagem as the paradigm. 

Schedule

1:00 PM  

What’s new in genetic & environmental triggers of AIBD / Dr. Murrell

1:25 PM  

New diagnostic techniques for AIBD / Dr. Marinovic

1:50 PM  

Biologics for Pemphigus / Dr. Joly

2:15 PM  

Biologics for Pemphigoid / Dr. Korman

2:40 PM  

New insights into Endemic pemphigus / Dr. Aoki

 

Download PDF